Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942151 | 1.00 | CNR1 (0.54) | CNR1SCN9AALDH1A1HTR2AHTR2C | |
| SCHEMBL5211637 | 0.86 | ALDH1A1 (0.68) | CNR1ALDH1A1KDM4E | |
| SCHEMBL17683584 | 0.83 | HTR2A (0.56) | CNR1ALDH1A1HTR2AHTR2CKDM4E | |
| SCHEMBL3069354 | 0.82 | KDM4E (0.68) | ALDH1A1KDM4E | |
| SCHEMBL6624875 | 0.82 | KDM4E (0.68) | CNR1ALDH1A1HTR2AHTR2CKDM4E | |
| SCHEMBL22769575 | 0.81 | ESR1 (0.60) | — | |
| SCHEMBL29819735 | 0.81 | ESR1 (0.60) | — | |
| SCHEMBL7964387 | 0.80 | KDM4E (0.53) | ALDH1A1KDM4E | |
| SCHEMBL3382621 | 0.80 | ALDH1A1 (0.73) | ALDH1A1KDM4E | |
| SCHEMBL30254999 | 0.80 | ALDH1A1 (0.73) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| US-8841320-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2014-09-23 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8372868-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8323621-B2 | site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle | VANDERBILT UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | VANDERBILT UNIVERSITY | 2010-11-04 | — | — | US | disclosed |
| US-7754884-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080241873-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | BORNHOP DARRYL J | 2008-10-02 | — | — | US | disclosed |
| US-20080241074-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | VANDERBILT UNIVERSITY | 2008-10-02 | — | — | US | disclosed |
| US-20030129579-A1 | Formed from 1,4,7,10 tetraazacyclododecane having varying chelating ions, phosphoester chains, and light harvesting moieties. | VANDERBILT UNIVERSITY | 2003-07-10 | — | — | US | disclosed |
| EP-1324985-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003020701-A2 | MULTI-USE MULTIMODAL IMAGING CHELATES | TEXAS TECH UNIVERSITY (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2002028831-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| EP-0546164-A1 | INDOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | FIDIA RESEARCH FOUNDATION (US) | 1993-06-16 | — | — | EP | disclosed |
| US-5206382-A | INDOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | FIDIA GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1993-04-27 | — | — | US | disclosed |
| WO-1993000334-A1 | INDOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | FIDIA - GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1993-01-07 | — | — | WO | disclosed |
| US-4139634-A | ANTIDEPRESSANTS, ANTIAGGRESSION AGENTS, ANESTHETICS | LABAZ (FR) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | TSPO, MKI67, GABRA4 | CNR1 8/4885SCN9A 2317/4885ALDH1A1 881/4885 |
| US-20080241074-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | PCNA, CLTC, CLTB | CNR1 1319/4885SCN9A 2051/4885ALDH1A1 3987/4885 |
| US-20030129579-A1 | Formed from 1,4,7,10 tetraazacyclododecane having varying chelating ions, phosphoester chains, and light harvesting moieties. | PCNA, CLTC, PHOSPHO1 | CNR1 1307/4885SCN9A 1372/4885ALDH1A1 3803/4885 |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | TSPO, MKI67, GABRA4 | CNR1 8/4885SCN9A 2317/4885ALDH1A1 881/4885 |
| US-20080241873-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | PCNA, CLTC, CLTB | CNR1 1319/4885SCN9A 2051/4885ALDH1A1 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.